Compare Stocks: MCRB, GLSI, NERV, and DTIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$6.99 -0.1%	$7.35	$3.53 ▼ $9.62	$180.36M	1.25	439,454 shs	211,109 shs
GLSI Greenwich LifeSciences	$13.50 -3.7%	$20.79	$7.78 ▼ $34.10	$198.15M	1.4	178,018 shs	85,402 shs
MCRB Seres Therapeutics	$4.83 +1.0%	$6.44	$4.59 ▼ $29.98	$46.77M	0.09	92,339 shs	51,175 shs
NERV Minerva Neurosciences	$3.98 -1.0%	$4.60	$1.76 ▼ $12.46	$185.42M	-0.16	169,066 shs	70,699 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	0.00%	-4.12%	-14.55%	-3.98%	+45.63%
GLSI Greenwich LifeSciences	0.00%	+4.01%	-38.64%	-43.04%	+20.00%
MCRB Seres Therapeutics	0.00%	-2.82%	-37.60%	-36.53%	-66.46%
NERV Minerva Neurosciences	0.00%	-1.49%	-21.96%	-34.43%	+110.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$6.99 -0.1%	$7.35	$3.53 ▼ $9.62	$180.36M	1.25	439,454 shs	211,109 shs
GLSI Greenwich LifeSciences	$13.50 -3.7%	$20.79	$7.78 ▼ $34.10	$198.15M	1.4	178,018 shs	85,402 shs
MCRB Seres Therapeutics	$4.83 +1.0%	$6.44	$4.59 ▼ $29.98	$46.77M	0.09	92,339 shs	51,175 shs
NERV Minerva Neurosciences	$3.98 -1.0%	$4.60	$1.76 ▼ $12.46	$185.42M	-0.16	169,066 shs	70,699 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	0.00%	-4.12%	-14.55%	-3.98%	+45.63%
GLSI Greenwich LifeSciences	0.00%	+4.01%	-38.64%	-43.04%	+20.00%
MCRB Seres Therapeutics	0.00%	-2.82%	-37.60%	-36.53%	-66.46%
NERV Minerva Neurosciences	0.00%	-1.49%	-21.96%	-34.43%	+110.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	361.37% Upside
GLSI Greenwich LifeSciences	2.33	Hold	$57.00	322.22% Upside
MCRB Seres Therapeutics	2.25	Hold	$17.00	251.97% Upside
NERV Minerva Neurosciences	2.00	Hold	$10.50	163.82% Upside

Current Analyst Ratings Breakdown

Latest MCRB, GLSI, NERV, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2026	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $69.00
7/9/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	MCRB Seres Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/23/2026	MCRB Seres Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/23/2026	MCRB Seres Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/9/2026	DTIL Precision BioSciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/27/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
5/18/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
5/15/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/8/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$34.26M	5.26	N/A	N/A	$4.03 per share	1.73
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A
MCRB Seres Therapeutics	$1.15M	40.78	$1.09 per share	4.45	$4.89 per share	0.99
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	-$45.72M	-$3.67	N/A	N/A	N/A	-96.73%	-85.37%	-37.34%	8/6/2026 (Estimated)
GLSI Greenwich LifeSciences	-$19.36M	-$1.57	N/A	N/A	N/A	N/A	-941.15%	-368.53%	8/13/2026 (Estimated)
MCRB Seres Therapeutics	$5.70M	-$5.17	N/A	N/A	N/A	N/A	-130.29%	-35.35%	8/5/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$29.16	N/A	0.83	N/A	N/A	N/A	-32.63%	8/13/2026 (Estimated)

Latest MCRB, GLSI, NERV, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.71	N/A	N/A	N/A	$1.40 million	N/A
8/5/2026	Q2 2026	MCRB Seres Therapeutics	-$2.1850	N/A	N/A	N/A	$0.18 million	N/A
5/5/2026	Q1 2026	DTIL Precision BioSciences	-$0.6550	-$0.75	-$0.0950	-$0.75	$4.05 million	$10.84 million
5/5/2026	Q1 2026	MCRB Seres Therapeutics	-$1.88	-$2.08	-$0.20	-$2.08	$0.36 million	$0.36 million
5/5/2026	Q1 2026	NERV Minerva Neurosciences	-$0.13	-$0.17	-$0.04	-$2.86	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.29	14.02	14.02
GLSI Greenwich LifeSciences	N/A	2.01	2.01
MCRB Seres Therapeutics	N/A	1.65	1.65
NERV Minerva Neurosciences	N/A	17.65	17.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
GLSI Greenwich LifeSciences	4.16%
MCRB Seres Therapeutics	59.34%
NERV Minerva Neurosciences	34.56%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	2.70%
GLSI Greenwich LifeSciences	51.47%
MCRB Seres Therapeutics	5.20%
NERV Minerva Neurosciences	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	200	25.80 million	25.11 million	No Data
GLSI Greenwich LifeSciences	3	14.68 million	7.12 million	Not Optionable
MCRB Seres Therapeutics	330	9.68 million	9.18 million	Optionable
NERV Minerva Neurosciences	9	46.59 million	45.80 million	Not Optionable

MCRB, GLSI, NERV, and DTIL Headlines

Recent News About These Companies

Seven Fleet Capital Management LP Makes New Investment in Minerva Neurosciences, Inc $NERV

August 2 at 6:31 AM | marketbeat.com

889,254 Shares in Minerva Neurosciences, Inc $NERV Bought by DV Trading LLC

August 2 at 4:23 AM | marketbeat.com

Minerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?

July 10, 2026 | marketbeat.com

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

June 1, 2026 | globenewswire.com

Minerva Neurosciences Launches ATM Offering to Fund Trial

May 27, 2026 | tipranks.com

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

May 20, 2026 | zacks.com

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 18, 2026 | globenewswire.com

Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026 | finanznachrichten.de

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026 | globenewswire.com

Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69

April 28, 2026 | msn.com

Citizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform Recommendation

April 16, 2026 | msn.com

Minerva launched with New Outperform at Citizens on schizophrenia candidate

April 15, 2026 | seekingalpha.com

Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline

April 6, 2026 | tipranks.com

Minerva Announces Leadership Transition

April 2, 2026 | globenewswire.com

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

March 31, 2026 | globenewswire.com

Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia

March 31, 2026 | seekingalpha.com

Minerva Neurosciences (NERV) price target increased by 61.11% to 7.40

March 27, 2026 | msn.com

Minerva Neurosciences, Inc: Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

March 25, 2026 | finanznachrichten.de

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

March 25, 2026 | globenewswire.com

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

March 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, GLSI, NERV, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

$6.99 -0.01 (-0.14%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$7.00 +0.00 (+0.07%)

As of 07/31/2026 07:33 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Greenwich LifeSciences NASDAQ:GLSI

$13.50 -0.52 (-3.71%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$13.96 +0.47 (+3.44%)

As of 07/31/2026 07:34 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Seres Therapeutics NASDAQ:MCRB

$4.83 +0.05 (+1.05%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.82 -0.01 (-0.21%)

As of 07/31/2026 07:34 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Minerva Neurosciences NASDAQ:NERV

$3.98 -0.04 (-1.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$3.98 0.00 (-0.13%)

As of 07/31/2026 07:34 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, GLSI, NERV, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, GLSI, NERV, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, GLSI, NERV, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, GLSI, NERV, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

Greenwich LifeSciences NASDAQ:GLSI

Seres Therapeutics NASDAQ:MCRB

Minerva Neurosciences NASDAQ:NERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, GLSI, NERV, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, GLSI, NERV, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, GLSI, NERV, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, GLSI, NERV, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

Greenwich LifeSciences NASDAQ:GLSI

Seres Therapeutics NASDAQ:MCRB

Minerva Neurosciences NASDAQ:NERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools